Thermo Fisher Scientific (TMO) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Oct. 02, 2021shares
Entity Listings [Line Items]
Entity Central Index Key	0000097745
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 2, 2021
Document Transition Report	false
Entity File Number	1-8002
Entity Registrant Name	THERMO FISHER SCIENTIFIC INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2209186
Entity Address, Address Line One	168 Third Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
City Area Code	781
Local Phone Number	622-1000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	394,048,087
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Common Stock, $1.00 par value
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	TMO
Security Exchange Name	NYSE
0.750% Notes due 2024
Entity Listings [Line Items]
Title of 12(b) Security	0.750% Notes due 2024
Trading Symbol	TMO 24A
Security Exchange Name	NYSE
Senior Notes 0.125% Due 2025 [Member]
Entity Listings [Line Items]
Title of 12(b) Security	0.125% Notes due 2025
Trading Symbol	TMO 25B
Security Exchange Name	NYSE
2.000% Notes due 2025
Entity Listings [Line Items]
Title of 12(b) Security	2.000% Notes due 2025
Trading Symbol	TMO 25
Security Exchange Name	NYSE
1.400% Notes due 2026
Entity Listings [Line Items]
Title of 12(b) Security	1.400% Notes due 2026
Trading Symbol	TMO 26A
Security Exchange Name	NYSE
1.450% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.450% Notes due 2027
Trading Symbol	TMO 27
Security Exchange Name	NYSE
1.750% Notes due 2027
Entity Listings [Line Items]
Title of 12(b) Security	1.750% Notes due 2027
Trading Symbol	TMO 27B
Security Exchange Name	NYSE
0.500% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	0.500% Notes due 2028
Trading Symbol	TMO 28A
Security Exchange Name	NYSE
1.375% Notes due 2028
Entity Listings [Line Items]
Title of 12(b) Security	1.375% Notes due 2028
Trading Symbol	TMO 28
Security Exchange Name	NYSE
1.950% Notes due 2029
Entity Listings [Line Items]
Title of 12(b) Security	1.950% Notes due 2029
Trading Symbol	TMO 29
Security Exchange Name	NYSE
0.875% Notes due 2031
Entity Listings [Line Items]
Title of 12(b) Security	0.875% Notes due 2031
Trading Symbol	TMO 31
Security Exchange Name	NYSE
2.375% Notes due 2032
Entity Listings [Line Items]
Title of 12(b) Security	2.375% Notes due 2032
Trading Symbol	TMO 32
Security Exchange Name	NYSE
2.875% Notes due 2037
Entity Listings [Line Items]
Title of 12(b) Security	2.875% Notes due 2037
Trading Symbol	TMO 37
Security Exchange Name	NYSE
1.500% Notes due 2039
Entity Listings [Line Items]
Title of 12(b) Security	1.500% Notes due 2039
Trading Symbol	TMO 39
Security Exchange Name	NYSE
1.875% Notes due 2049
Entity Listings [Line Items]
Title of 12(b) Security	1.875% Notes due 2049
Trading Symbol	TMO 49
Security Exchange Name	NYSE

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 12,027	$ 10,325
Accounts receivable, less allowances of $138 and $135	5,557	5,741
Inventories	4,906	4,029
Contract assets, net	808	731
Other current assets	1,426	1,131
Total current assets	24,724	21,957
Property, Plant and Equipment, Net	7,049	5,912
Acquisition-related Intangible Assets, Net	11,927	12,685
Other Assets	2,991	2,457
Goodwill	26,909	26,041
Total Assets	73,600	69,052
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	19	2,628
Accounts payable	2,301	2,175
Accrued payroll and employee benefits	1,816	1,916
Contract liabilities	1,442	1,271
Other accrued expenses	2,175	2,314
Total current liabilities	7,753	10,304
Deferred Income Taxes	1,465	1,794
Other Long-term Liabilities	3,984	3,340
Long-term Obligations	21,688	19,107
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 438,749,893 and 437,088,297 shares issued	439	437
Capital in excess of par value	15,960	15,579
Retained earnings	33,876	28,116
Treasury stock at cost, 44,701,806 and 40,417,789 shares	(8,911)	(6,818)
Accumulated other comprehensive items	(2,654)	(2,807)
Total shareholders' equity	38,710	34,507
Total Liabilities and Shareholders' Equity	$ 73,600	$ 69,052

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$ 138	$ 135
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$ 100	$ 100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$ 1	$ 1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	438,749,893	437,088,297
Treasury Stock at Cost (in shares)	44,701,806	40,417,789

Consolidated Statement of Incom

Consolidated Statement of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Revenues
Revenues	$ 9,330	$ 8,521	$ 28,509	$ 21,668
Costs and Operating Expenses:
Selling, general and administrative expenses	2,004	1,592	5,729	4,853
Research and development expenses	351	296	1,014	805
Restructuring and other costs	18	17	151	67
Total costs and operating expenses	7,052	6,095	21,019	16,945
Operating Income	2,278	2,426	7,490	4,723
Interest Income	9	9	32	53
Interest Expense	(128)	(144)	(375)	(407)
Other Income (Expense)	14	(39)	(174)	(36)
Income Before Income Taxes	2,173	2,252	6,973	4,333
Provision for Income Taxes	(271)	(319)	(906)	(456)
Net Income	$ 1,902	$ 1,933	$ 6,067	$ 3,877
Earnings per Share
Basic (in dollars per share)	$ 4.83	$ 4.88	$ 15.41	$ 9.79
Diluted (in dollars per share)	$ 4.79	$ 4.84	$ 15.29	$ 9.71
Weighted Average Shares
Basic (in shares)	394	396	394	396
Diluted (in shares)	397	399	397	399
Product [Member]
Revenues
Revenues	$ 7,360	$ 6,782	$ 22,430	$ 16,662
Costs and Operating Expenses:
Cost of revenues	3,298	3,001	9,977	7,732
Service [Member]
Revenues
Revenues	1,970	1,739	6,079	5,006
Costs and Operating Expenses:
Cost of revenues	$ 1,381	$ 1,189	$ 4,148	$ 3,488

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Comprehensive Income
Net income	$ 1,902	$ 1,933	$ 6,067	$ 3,877
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $74, $(76), $169 and $(71))	(32)	10	121	(244)
Unrealized gains and losses on hedging instruments:
Unrealized losses on hedging instruments (net of tax benefit of $0, $0, $0 and $20)	0	0	0	(65)
Reclassification adjustment for losses included in net income (net of tax benefit of $0, $2, $5 and $4)	2	6	16	10
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (provision) benefit of $(1), $1, $(3) and $2)	3	(4)	7	(5)
Amortization of net loss included in net periodic pension cost (net of tax benefit of $2, $1, $4 and $4)	3	7	9	13
Total other comprehensive items	(24)	19	153	(291)
Comprehensive Income	$ 1,878	$ 1,952	$ 6,220	$ 3,586

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Statement of Comprehensive Income [Abstract]
Tax provision (benefit) on currency translation adjustment	$ 74	$ (76)	$ 169	$ (71)
Tax benefit on unrealized holding losses on hedging instruments arising during the period	0	0	0	20
Tax benefit on reclassification adjustment for losses on hedging instruments recognized in net income	0	2	5	4
Tax benefit (provision) on pension and other postretirement benefit liability adjustments arising during the period	(1)	1	(3)	2
Tax benefit on amortization of net loss and prior service benefit included in net periodic pension cost	$ 2	$ 1	$ 4	$ 4

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020
Operating Activities
Net income	$ 6,067	$ 3,877
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	614	467
Amortization of acquisition-related intangible assets	1,295	1,256
Change in deferred income taxes	(455)	(496)
Loss on early extinguishment of debt	197	0
Stock-based compensation	153	145
Other non-cash expenses, net	194	209
Changes in assets and liabilities, excluding the effects of acquisitions	(1,210)	(508)
Net cash provided by operating activities	6,855	4,950
Investing Activities
Acquisitions, net of cash acquired	(1,519)	(3)
Purchase of property, plant and equipment	(1,692)	(888)
Proceeds from sale of property, plant and equipment	9	7
Other investing activities, net	(38)	0
Net cash used in investing activities	(3,240)	(884)
Financing Activities
Net proceeds from issuance of debt	3,122	3,464
Repayment of debt	(2,807)	(712)
Proceeds from issuance of commercial paper	0	383
Repayments of commercial paper	0	(387)
Purchases of company common stock	(2,000)	(1,500)
Dividends paid	(292)	(250)
Net proceeds from issuance of company common stock under employee stock plans	101	156
Other financing activities, net	(10)	(146)
Net cash (used in) provided by financing activities	(1,886)	1,008
Exchange Rate Effect on Cash	(17)	74
Increase in Cash, Cash Equivalents and Restricted Cash	1,712	5,148
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	10,336	2,422
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 12,048	$ 7,570

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Retained Earnings [Member]Cumulative Effect, Period of Adoption, Adjustment [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
Balance (in shares) at Dec. 31, 2019			434				36
Balance at Dec. 31, 2019	$ 29,675	$ (1)	$ 434	$ 15,064	$ 22,092	$ (1)	$ (5,236)	$ (2,679)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			3				0
Issuance of shares under employees' and directors' stock plans	182		$ 3	258			$ (79)
Stock-based compensation	145			145
Purchases of company common stock (in shares)							4
Purchases of company common stock	(1,500)						$ (1,500)
Dividends declared	(263)				(263)
Net income	3,877				3,877
Other comprehensive items	(291)							(291)
Balance (in shares) at Sep. 26, 2020			437				40
Balance at Sep. 26, 2020	31,824		$ 437	15,467	25,705		$ (6,815)	(2,970)
Balance (in shares) at Jun. 27, 2020			436				40
Balance at Jun. 27, 2020	29,875		$ 436	15,334	23,860		$ (6,766)	(2,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				0
Issuance of shares under employees' and directors' stock plans	33		$ 1	81			$ (49)
Stock-based compensation	52			52
Dividends declared	(88)				(88)
Net income	1,933				1,933
Other comprehensive items	19							19
Balance (in shares) at Sep. 26, 2020			437				40
Balance at Sep. 26, 2020	31,824		$ 437	15,467	25,705		$ (6,815)	(2,970)
Balance (in shares) at Dec. 31, 2020			437				40
Balance at Dec. 31, 2020	34,507		$ 437	15,579	28,116		$ (6,818)	(2,807)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			2				1
Issuance of shares under employees' and directors' stock plans	137		$ 2	228			$ (93)
Stock-based compensation	153			153
Purchases of company common stock (in shares)							4
Purchases of company common stock	(2,000)						$ (2,000)
Dividends declared	(307)				(307)
Net income	6,067				6,067
Other comprehensive items	153							153
Balance (in shares) at Oct. 02, 2021			439				45
Balance at Oct. 02, 2021	38,710		$ 439	15,960	33,876		$ (8,911)	(2,654)
Balance (in shares) at Jul. 03, 2021			438				45
Balance at Jul. 03, 2021	36,854		$ 438	15,826	32,076		$ (8,856)	(2,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)			1				0
Issuance of shares under employees' and directors' stock plans	29		$ 1	83			$ (55)
Stock-based compensation	51			51
Dividends declared	(102)				(102)
Net income	1,902				1,902
Other comprehensive items	(24)							(24)
Balance (in shares) at Oct. 02, 2021			439				45
Balance at Oct. 02, 2021	$ 38,710		$ 439	$ 15,960	$ 33,876		$ (8,911)	$ (2,654)

Consolidated Statement of Sha_2

Consolidated Statement of Shareholders' Equity Consolidated Statement of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Cash Dividends Declared per Common Share (in dollars per share)	$ 0.26	$ 0.22	$ 0.78	$ 0.66

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Oct. 02, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and therapies, and increase laboratory productivity. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. Interim Financial Statements The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at October 2, 2021, the results of operations for the three- and nine-month periods ended October 2, 2021 and September 26, 2020, and the cash flows for the nine-month periods ended October 2, 2021 and September 26, 2020. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet presented as of December 31, 2020, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2020 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation. Note 1 to the consolidated financial statements for 2020 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the nine months ended October 2, 2021. Inventories The components of inventories are as follows: October 2, December 31, (In millions) 2021 2020 Raw Materials $ 1,840 $ 1,305 Work in Process 680 540 Finished Goods 2,386 2,184 Inventories $ 4,906 $ 4,029 Prior to the third quarter of 2021, certain of the company’s businesses utilized the last-in, first-out (LIFO) method of accounting for inventories. During the third quarter of 2021, these businesses, which comprise approximately 5% of consolidated inventories, changed from the LIFO method to the first-in, first-out (FIFO) method. The company believes this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third quarter of 2021. This change was recorded in the Laboratory Products and Services ($20 million) and Specialty Diagnostics ($13 million) segments. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three segments. The negative impacts have significantly lessened so far in 2021. The extent and duration of negative impacts in the future, which may include inflationary pressures and supply chain disruptions, are uncertain and may require changes to estimates. Actual results could differ from those estimates. Recent Accounting Pronouncements In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company will adopt this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance will not have a material impact on the company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations. In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.

Acquisitions

Acquisitions	9 Months Ended
	Oct. 02, 2021
Business Combinations [Abstract]
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Pending Acquisition On April 15, 2021, the company entered into a definitive agreement under which it will acquire PPD, Inc. for $47.50 per share for a total cash purchase price of $17.4 billion plus the assumption of approximately $3.5 billion of net debt. PPD provides a broad range of clinical research and specialized laboratory services to enable customers to accelerate innovation and increase drug development productivity. Upon close of the transaction, PPD will become part of the Laboratory Products and Services Segment. Shareholders holding in aggregate approximately 60% of the issued and outstanding shares of common stock of PPD on April 15, 2021, have approved the transaction by written consent. No further action by other PPD shareholders is required to approve the transaction. On July 16, 2021, the company and PPD each received a request for additional information and documentary materials (collectively, the “Second Request”) from the U.S. Federal Trade Commission (FTC), in connection with the FTC’s review of the proposed merger. The effect of the Second Request is to extend the waiting period imposed under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), until the 30th day after substantial compliance by the company and PPD with the Second Request, unless the waiting period is terminated earlier by the FTC. As of October 22, 2021, both the company and PPD had certified substantial compliance with the Second Request. The transaction remains subject to the satisfaction of customary closing conditions, including termination of the HSR Act waiting period and receipt of applicable regulatory approvals outside the U.S. Subject to the satisfaction of the required closing conditions, we continue to expect the merger to be completed by the end of 2021. 2021 On January 15, 2021, the company acquired, within the Laboratory Products and Services segment, the Belgium-based European viral vector manufacturing business of Groupe Novasep SAS for $834 million in net cash consideration. The European viral vector manufacturing business provides manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and therapies. The goodwill recorded as a result of this business combination is not tax deductible. On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company, for $409 million in net cash consideration and contingent consideration with an initial fair value of $65 million due upon the completion of certain milestones. Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible. On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Services segment, of a new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers as well. The company expects to make fixed lease payments aggregating to $555 million (excluding renewals) from 2021 to 2041, with additional amounts dependent on the extent of revenues from customers of the facility other than CSL. The goodwill recorded as a result of this business combination is not tax deductible. In addition, in the first nine months of 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor and a developer of a digital PCR platform and, within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid chromatography columns. The components of the purchase prices and the allocations to the net assets acquired for 2021 acquisitions are as follows: (In millions) European Viral Vector Business Mesa Biotech Lengnau biologics manufacturing facility Other Purchase Price Cash paid $ 853 $ 423 $ — $ 287 Fair value of contingent consideration — 65 1 113 Purchase price payable — — 17 — Cash acquired (19) (14) — (11) $ 834 $ 474 $ 18 $ 389 Net Assets Acquired Current assets $ 39 $ 54 $ — $ 10 Property, plant and equipment 59 2 92 3 Definite-lived intangible assets: Customer relationships 302 — — 2 Product technology 25 279 — 220 Tradenames — 2 — 3 Goodwill 603 239 18 190 Other assets 4 4 361 — Contract liabilities (59) — — (1) Deferred tax liabilities (80) (72) — (28) Finance lease liabilities (24) (1) (82) — Other liabilities assumed (35) (33) (371) (10) $ 834 $ 474 $ 18 $ 389 The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 14 years for customer relationships, 7 years for product technology and 3 years for tradenames. The weighted average amortization period for all definite-lived intangible assets acquired in 2021 is 9 years. The allocation of the purchase price for the Lengnau biologics manufacturing facility is preliminary, principally with respect to lease assets and liabilities as well as deferred taxes.

Revenue and Contract-related Ba

Revenue and Contract-related Balances	9 Months Ended
	Oct. 02, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 3. Revenues and Contract-related Balances Disaggregated Revenues Revenues by type are as follows: Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues Consumables 5,544 4,956 $ 16,880 $ 12,214 Instruments 1,816 1,826 5,550 4,448 Services 1,970 1,739 6,079 5,006 Consolidated revenues $ 9,330 $ 8,521 $ 28,509 $ 21,668 Revenues by geographic region based on customer location are as follows: Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues North America $ 4,662 $ 4,587 $ 14,292 $ 11,418 Europe 2,557 2,032 8,037 5,464 Asia-Pacific 1,836 1,607 5,294 4,054 Other regions 275 295 886 732 Consolidated revenues $ 9,330 $ 8,521 $ 28,509 $ 21,668 Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for revenues by reportable segment and other geographic data. Remaining Performance Obligations The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of October 2, 2021 was $14.49 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 76% of which is expected to occur within the next twelve months. Contract-related Balances Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: October 2, December 31, (In millions) 2021 2020 Current Contract Assets, Net $ 808 $ 731 Noncurrent Contract Assets, Net 11 11 Current Contract Liabilities 1,442 1,271 Noncurrent Contract Liabilities 822 763

Business Segment and Geographic

Business Segment and Geographical Information	9 Months Ended
	Oct. 02, 2021
Segment Reporting [Abstract]
Business Segment and Geographical Information [Text Block]	Note 4. Business Segment and Geographical Information Business Segment Information Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues Life Sciences Solutions $ 3,721 $ 3,424 $ 11,481 $ 7,800 Analytical Instruments 1,476 1,336 4,344 3,488 Specialty Diagnostics 1,362 1,430 4,212 3,376 Laboratory Products and Services 3,487 3,112 10,667 8,629 Eliminations (716) (781) (2,195) (1,625) Consolidated revenues 9,330 8,521 28,509 21,668 Segment Income Life Sciences Solutions 1,821 1,879 5,818 3,788 Analytical Instruments 264 171 816 477 Specialty Diagnostics 310 398 983 848 Laboratory Products and Services 383 355 1,360 931 Subtotal reportable segments 2,778 2,803 8,977 6,044 Cost of revenues charges — (1) (8) (5) Selling, general and administrative (charges) credits (59) 55 (33) 7 Restructuring and other costs (18) (17) (151) (67) Amortization of acquisition-related intangible assets (423) (414) (1,295) (1,256) Consolidated operating income 2,278 2,426 7,490 4,723 Interest income 9 9 32 53 Interest expense (128) (144) (375) (407) Other income (expense) 14 (39) (174) (36) Income before income taxes $ 2,173 $ 2,252 $ 6,973 $ 4,333 Geographical Information Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues (a) United States $ 4,495 $ 4,428 $ 13,742 $ 10,981 China 885 828 2,454 1,886 Other 3,950 3,265 12,313 8,801 Consolidated revenues $ 9,330 $ 8,521 $ 28,509 $ 21,668 (a) Revenues are attributed to countries based on customer location.

Income Taxes

Income Taxes	9 Months Ended
	Oct. 02, 2021
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 5. Income Taxes The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine Months Ended October 2, September 26, (In millions) 2021 2020 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 1,464 $ 910 Increases (Decreases) Resulting From: Foreign rate differential (159) (132) Income tax credits (205) (205) Global intangible low-taxed income 45 82 Foreign-derived intangible income (114) (53) Excess tax benefits from stock options and restricted stock units (96) (94) Intra-entity transfers (258) — Withholding taxes 106 10 State income taxes, net of federal tax 115 29 Other, net 8 (91) Provision for Income Taxes $ 906 $ 456 The company has operations and a taxable presence in approximately 50 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. Unrecognized Tax Benefits As of October 2, 2021, the company had $1.12 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2021 Balance at Beginning of Year $ 1,091 Additions for tax positions of current year 30 Additions for tax positions of prior years 15 Reductions for tax positions of prior years (2) Settlements (16) Balance at End of Period $ 1,118

Earnings Per Share

Earnings Per Share	9 Months Ended
	Oct. 02, 2021
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 6. Earnings per Share Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions except per share amounts) 2021 2020 2021 2020 Net Income $ 1,902 $ 1,933 $ 6,067 $ 3,877 Basic Weighted Average Shares 394 396 394 396 Plus Effect of: Stock options and restricted stock units 3 3 3 3 Diluted Weighted Average Shares 397 399 397 399 Basic Earnings per Share $ 4.83 $ 4.88 $ 15.41 $ 9.79 Diluted Earnings per Share $ 4.79 $ 4.84 $ 15.29 $ 9.71 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares — — 1 1

Debt and Other Financing Arrang

Debt and Other Financing Arrangements	9 Months Ended
	Oct. 02, 2021
Debt Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 7. Debt and Other Financing Arrangements Effective Interest Rate at October 2, October 2, December 31, (Dollars in millions) 2021 2021 2020 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) $ — $ 611 3.00% 7-Year Senior Notes, Due 4/15/2023 — 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 — 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,159 1,222 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.42 % 928 977 4.133% 5-Year Senior Notes, Due 3/25/2025 4.32 % 1,100 1,100 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 742 782 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 812 855 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 580 611 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 696 733 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.78 % 928 977 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 696 733 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 — 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 812 855 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.31 % 1,100 1,100 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.14 % 1,043 1,099 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 — 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 696 733 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 812 855 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,043 1,099 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 — 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.99 % 1,159 1,222 Other 77 5 Total Borrowings at Par Value 21,833 21,919 Fair Value Hedge Accounting Adjustments — 25 Unamortized Discount (107) (102) Unamortized Debt Issuance Costs (128) (114) Total Borrowings at Carrying Value 21,598 21,728 Finance Lease Liabilities 109 7 Less: Short-term Obligations and Current Maturities 19 2,628 Long-term Obligations $ 21,688 $ 19,107 The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount and the amortization of any debt issuance costs. See Note 10 for fair value information pertaining to the company’s long-term borrowings. In connection with the agreement to acquire PPD (Note 2), the company had a cash outlay of $35 million in 2021 associated with obtaining bridge financing commitments, included in other financing activities, net, in the accompanying statement of cash flows. The bridge commitments were terminated in October 2021 upon the issuances of senior notes. The company intends to finance the purchase price with cash on hand and the net proceeds from issuances of debt, including the senior notes issued in October 2021. The company is currently evaluating a future debt offering and the timing of such transaction is subject to market and other conditions. Credit Facilities The company has a revolving credit facility (the Facility) with a bank group that provides for up to $3.00 billion of unsecured multi-currency revolving credit. The Facility expires on December 4, 2025. The revolving credit agreement calls for interest at either a LIBOR-based rate (or LIBOR successor rate), a EURIBOR-based rate (for funds drawn in euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of October 2, 2021, no borrowings were outstanding under the Facility, although available capacity was reduced by approximately $4 million as a result of outstanding letters of credit. Commercial Paper Programs The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of October 2, 2021, there were no outstanding borrowings under these programs. Senior Notes Interest is payable annually on the euro-denominated senior notes and semi-annually on all other senior notes. Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements. The company was in compliance with all covenants at October 2, 2021. In the first quarter of 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $197 million of losses on the early extinguishment of debt included in Other Income (Expense) on the accompanying statement of income. Upon redemption of the senior notes, the company terminated the related fixed to floating rate interest rate swap arrangements and received $22 million, included in other financing activities, net, in the accompanying statement of cash flows. October 2021 Debt Issuances Early in the fourth quarter, the company issued the following senior notes: (In millions) Principal Value Issued Floating Rate 18-Month Senior Notes, Due 4/18/2023 $ 1,000 Floating Rate 2-Year Senior Notes, Due 10/18/2023 $ 500 0.797% 2-Year Senior Notes, Due 10/18/2023 $ 1,350 Floating Rate 3-Year Senior Notes, Due 10/18/2024 $ 500 1.215% 3-Year Senior Notes, Due 10/18/2024 $ 2,500 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) € 1,750 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) € 1,500 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) € 1,250 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) € 750

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 02, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Note 8. Commitments and Contingencies Environmental Matters The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At October 2, 2021, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2020 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows. Litigation and Related Contingencies The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company's 2020 financial statements and notes included in the company's Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows. Product Liability, Workers Compensation and Other Personal Injury Matters The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. At October 2, 2021, there have been no material changes to the accruals for pending product liability, workers compensation, and other personal injury matters disclosed in the company’s 2020 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis. Loss on Supply Agreement In the third quarter of 2020, the Analytical Instruments segment recorded a charge to cost of product revenues for $108 million related to an existing supply contract for components of electron microscopy instruments. The agreement requires the company to make future minimum purchases through 2025. The company developed and launched an alternative product beginning in 2020 and based on the expected demand for the internally developed product vs. the third-party product, the company does not expect to use all of the product it will be required to buy, resulting in a loss on the purchase commitment.

Comprehensive Income

Comprehensive Income	9 Months Ended
	Oct. 02, 2021
Stockholders' Equity Note [Abstract]
Comprehensive Income and Shareholders' Equity [Text Block]	Note 9. Comprehensive Income Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2020 $ (2,438) $ (91) $ (278) $ (2,807) Other comprehensive items before reclassifications 121 — 7 128 Amounts reclassified from accumulated other comprehensive items — 16 9 25 Net other comprehensive items 121 16 16 153 Balance at October 2, 2021 $ (2,317) $ (75) $ (262) $ (2,654)

Fair Value Measurements and Fai

Fair Value Measurements and Fair Value of Financial Instruments	9 Months Ended
	Oct. 02, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 10. Fair Value Measurements and Fair Value of Financial Instruments Fair Value Measurements The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis as of October 2, 2021 and December 31, 2020: October 2, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 10,518 $ 10,518 $ — $ — Investments in common stock, mutual funds and other similar instruments 61 61 — — Warrants 18 — 18 — Insurance contracts 178 — 178 — Derivative contracts 75 — 75 — Total Assets $ 10,850 $ 10,579 $ 271 $ — Liabilities Derivative contracts $ 4 $ — $ 4 $ — Contingent consideration 171 — — 171 Total Liabilities $ 175 $ — $ 4 $ 171 December 31, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 8,971 $ 8,971 $ — $ — Investments in common stock, mutual funds and other similar instruments 21 21 — — Warrants 7 — 7 — Insurance contracts 157 — 157 — Derivative contracts 28 — 28 — Total Assets $ 9,184 $ 8,992 $ 192 $ — Liabilities Derivative contracts $ 132 $ — $ 132 $ — Contingent consideration 70 — — 70 Total Liabilities $ 202 $ — $ 132 $ 70 The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones), of the contingent consideration. Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Contingent Consideration Beginning Balance $ 149 $ 53 $ 70 $ 55 Acquisitions (including assumed balances) — — 179 — Payments (1) (1) (43) (3) Changes in fair value included in earnings 23 (8) (35) (8) Ending Balance $ 171 $ 44 $ 171 $ 44 Derivative Contracts The following table provides the aggregate notional value of outstanding derivative contracts. October 2, December 31, (In millions) 2021 2020 Notional Amount Interest rate swaps - fair value hedges $ — $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Currency exchange contracts 4,823 5,206 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheet and statement of income. Fair Value – Assets Fair Value – Liabilities October 2, December 31, October 2, December 31, (In millions) 2021 2020 2021 2020 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ 25 $ — $ — Cross-currency interest rate swaps (a) 10 — 4 46 Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 65 3 — 86 Total Derivatives $ 75 $ 28 $ 4 $ 132 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability October 2, December 31, October 2, December 31, (In millions) 2021 2020 2021 2020 Long-term Obligations $ — $ 1,020 $ — $ 25 Gain (Loss) Recognized Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other income (expense) $ — $ — $ 25 $ (43) Derivatives designated as hedging instruments - included in other income (expense) — — (3) 43 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — — — (85) Amount reclassified from accumulated other comprehensive items to other expense (2) (8) (21) (14) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 297 (295) 673 (276) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 20 (30) 52 (30) Included in other income (expense) 2 2 6 9 Gain (Loss) Recognized Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 7 (2) 8 (2) Included in other income (expense) (8) 51 147 7 Cross-currency interest rate swaps Included in other income (expense) — 1 — (9) Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. The company uses foreign currency-denominated debt and cross-currency interest rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The majority of the company’s euro-denominated senior notes and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments and contract fair value changes on the cross-currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity. See Note 1 to the consolidated financial statements for 2020 included in the company's Annual Report on Form 10-K for additional information on the company's risk management objectives and strategies. Fair Value of Other Financial Instruments The carrying value and fair value of the company’s debt instruments are as follows: October 2, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) Value Value Value Value Senior notes $ 21,521 $ 23,418 $ 21,723 $ 24,653 Other 77 77 5 5 $ 21,598 $ 23,495 $ 21,728 $ 24,658 The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Oct. 02, 2021
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 11. Supplemental Cash Flow Information Nine Months Ended October 2, September 26, (In millions) 2021 2020 Non-cash Investing and Financing Activities Acquired but unpaid property, plant and equipment $ 257 $ 134 Fair value of acquisition contingent consideration 179 — Declared but unpaid dividends 104 88 Issuance of stock upon vesting of restricted stock units 237 209 Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: October 2, December 31, (In millions) 2021 2020 Cash and Cash Equivalents $ 12,027 $ 10,325 Restricted Cash Included in Other Current Assets 20 10 Restricted Cash Included in Other Assets 1 1 Cash, Cash Equivalents and Restricted Cash $ 12,048 $ 10,336 Amounts included in restricted cash represent funds held as collateral for bank guarantees and incoming cash in China awaiting government administrative clearance.

Restructuring and Other Costs

Restructuring and Other Costs	9 Months Ended
	Oct. 02, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Other Costs, Net [Text Block]	Note 12. Restructuring and Other Costs In the first nine months of 2021 the company recorded restructuring and other costs primarily associated with charges for impairment of acquired technology and third-party transaction/integration costs related to recent acquisitions, partially offset by credits for changes in estimates of contingent acquisition consideration. In the first nine months of 2021, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce. As of November 4, 2021, the company has identified restructuring actions that will result in additional charges of approximately $25 million, primarily in 2021 and 2022, and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit arrangements or when the costs have been incurred. During the third quarter of 2021, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ 23 $ (3) $ 20 Analytical Instruments — 1 2 3 Specialty Diagnostics — — 14 14 Laboratory Products and Services — 26 (3) 23 Corporate — 9 8 17 $ — $ 59 $ 18 $ 77 During the first nine months of 2021, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 8 $ (24) $ 125 $ 109 Analytical Instruments — 1 5 6 Specialty Diagnostics — (2) 17 15 Laboratory Products and Services — 49 (5) 44 Corporate — 9 9 18 $ 8 $ 33 $ 151 $ 192 The principal components of net restructuring and other costs (income) by segment are as follows: Life Sciences Solutions In the first nine months of 2021, the Life Sciences Solutions segment recorded $125 million of restructuring and other costs, primarily charges of $110 million for impairment of acquired technology resulting from a reduction in expected cash flows, and compensation contractually due to employees of acquired businesses at the date of acquisition. The segment recorded $24 million of net credits to selling, general, and administrative expense, principally for changes in estimates of contingent acquisition consideration, partially offset by third-party transaction costs related to recent acquisitions. The segment also recorded $8 million of charges to cost of revenues for the sale of inventories revalued at the date of acquisition. Specialty Diagnostics In the first nine months of 2021, the Specialty Diagnostics segment recorded $17 million of net restructuring and other charges, primarily for severance and write-downs of fixed assets to estimated disposal value in connection with the discontinuation of a product line in Europe. Laboratory Products and Services In the first nine months of 2021, the Laboratory Products and Services segment recorded $44 million of net restructuring and other charges, primarily for third-party transaction/integration costs related to recent acquisitions. Corporate In the first nine months of 2021, the company recorded $18 million of net restructuring and other charges, primarily for product liability litigation and pre-acquisition related matters. The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2020 21 Net restructuring charges incurred in 2021 (b) 23 Payments (31) Currency translation (1) Balance at October 2, 2021 $ 12 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment. (b) Excludes $128 million of net charges, principally for impairment of acquired technology, compensation contractually due and paid to employees of acquired businesses at the date of acquisition, fixed asset write-downs, and charges associated with pre-acquisition related matters. The company expects to pay accrued restructuring costs primarily through 2021.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 02, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Risks and uncertainties associated with the ongoing COVID-19 global pandemic materially adversely affected certain of the company’s businesses in 2020, particularly in the Analytical Instruments segment and, to a lesser extent, some businesses within the other three
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In October 2021, the FASB amended guidance to recognize and measure contract assets and contract liabilities acquired in a business combination. Generally, this new guidance will result in the company recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The company will adopt this guidance in the fourth quarter of 2021 retrospectively to all business combinations completed in the first three quarters of 2021 and prospectively to all future business combinations. The adoption of this guidance will not have a material impact on the company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent on the contract assets and contract liabilities acquired in future business combinations. In July 2021, the FASB amended guidance to require lessors to classify leases as operating leases if they have certain variable lease payment structures and would have selling losses if they were classified as sales-type or direct financing leases. The company adopted the guidance in the third quarter of 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. Among other things, the new guidance requires the effects of enacted changes in tax laws or rates to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date. The company adopted this guidance in 2021 using a prospective method. The adoption of this guidance did not have a material impact on the company’s consolidated financial statements; however, the impact in future periods will be dependent on the extent of future events or conditions that would be affected such as enacted changes in tax laws or rates.
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Acquisitions (Policies)

Acquisitions (Policies)	9 Months Ended
	Oct. 02, 2021
Business Combinations [Abstract]
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforce. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products. Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 02, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventories [Table Text Block]	Inventories The components of inventories are as follows: October 2, December 31, (In millions) 2021 2020 Raw Materials $ 1,840 $ 1,305 Work in Process 680 540 Finished Goods 2,386 2,184 Inventories $ 4,906 $ 4,029

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Oct. 02, 2021
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The components of the purchase prices and the allocations to the net assets acquired for 2021 acquisitions are as follows: (In millions) European Viral Vector Business Mesa Biotech Lengnau biologics manufacturing facility Other Purchase Price Cash paid $ 853 $ 423 $ — $ 287 Fair value of contingent consideration — 65 1 113 Purchase price payable — — 17 — Cash acquired (19) (14) — (11) $ 834 $ 474 $ 18 $ 389 Net Assets Acquired Current assets $ 39 $ 54 $ — $ 10 Property, plant and equipment 59 2 92 3 Definite-lived intangible assets: Customer relationships 302 — — 2 Product technology 25 279 — 220 Tradenames — 2 — 3 Goodwill 603 239 18 190 Other assets 4 4 361 — Contract liabilities (59) — — (1) Deferred tax liabilities (80) (72) — (28) Finance lease liabilities (24) (1) (82) — Other liabilities assumed (35) (33) (371) (10) $ 834 $ 474 $ 18 $ 389

Revenue and Contract-related _2

Revenue and Contract-related Balances (Tables)	9 Months Ended
	Oct. 02, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	Disaggregated Revenues Revenues by type are as follows: Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues Consumables 5,544 4,956 $ 16,880 $ 12,214 Instruments 1,816 1,826 5,550 4,448 Services 1,970 1,739 6,079 5,006 Consolidated revenues $ 9,330 $ 8,521 $ 28,509 $ 21,668 Revenues by geographic region based on customer location are as follows: Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues North America $ 4,662 $ 4,587 $ 14,292 $ 11,418 Europe 2,557 2,032 8,037 5,464 Asia-Pacific 1,836 1,607 5,294 4,054 Other regions 275 295 886 732 Consolidated revenues $ 9,330 $ 8,521 $ 28,509 $ 21,668
Contract with Customer, Asset and Liability [Table Text Block]	Noncurrent contract assets are included within other assets in the accompanying balance sheet. Noncurrent contract liabilities are included within other long-term liabilities in the accompanying balance sheet. Contract asset and liability balances are as follows: October 2, December 31, (In millions) 2021 2020 Current Contract Assets, Net $ 808 $ 731 Noncurrent Contract Assets, Net 11 11 Current Contract Liabilities 1,442 1,271 Noncurrent Contract Liabilities 822 763

Business Segment and Geograph_2

Business Segment and Geographical Information (Tables)	9 Months Ended
	Oct. 02, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues Life Sciences Solutions $ 3,721 $ 3,424 $ 11,481 $ 7,800 Analytical Instruments 1,476 1,336 4,344 3,488 Specialty Diagnostics 1,362 1,430 4,212 3,376 Laboratory Products and Services 3,487 3,112 10,667 8,629 Eliminations (716) (781) (2,195) (1,625) Consolidated revenues 9,330 8,521 28,509 21,668 Segment Income Life Sciences Solutions 1,821 1,879 5,818 3,788 Analytical Instruments 264 171 816 477 Specialty Diagnostics 310 398 983 848 Laboratory Products and Services 383 355 1,360 931 Subtotal reportable segments 2,778 2,803 8,977 6,044 Cost of revenues charges — (1) (8) (5) Selling, general and administrative (charges) credits (59) 55 (33) 7 Restructuring and other costs (18) (17) (151) (67) Amortization of acquisition-related intangible assets (423) (414) (1,295) (1,256) Consolidated operating income 2,278 2,426 7,490 4,723 Interest income 9 9 32 53 Interest expense (128) (144) (375) (407) Other income (expense) 14 (39) (174) (36) Income before income taxes $ 2,173 $ 2,252 $ 6,973 $ 4,333
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues Life Sciences Solutions $ 3,721 $ 3,424 $ 11,481 $ 7,800 Analytical Instruments 1,476 1,336 4,344 3,488 Specialty Diagnostics 1,362 1,430 4,212 3,376 Laboratory Products and Services 3,487 3,112 10,667 8,629 Eliminations (716) (781) (2,195) (1,625) Consolidated revenues 9,330 8,521 28,509 21,668 Segment Income Life Sciences Solutions 1,821 1,879 5,818 3,788 Analytical Instruments 264 171 816 477 Specialty Diagnostics 310 398 983 848 Laboratory Products and Services 383 355 1,360 931 Subtotal reportable segments 2,778 2,803 8,977 6,044 Cost of revenues charges — (1) (8) (5) Selling, general and administrative (charges) credits (59) 55 (33) 7 Restructuring and other costs (18) (17) (151) (67) Amortization of acquisition-related intangible assets (423) (414) (1,295) (1,256) Consolidated operating income 2,278 2,426 7,490 4,723 Interest income 9 9 32 53 Interest expense (128) (144) (375) (407) Other income (expense) 14 (39) (174) (36) Income before income taxes $ 2,173 $ 2,252 $ 6,973 $ 4,333
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographical Information Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Revenues (a) United States $ 4,495 $ 4,428 $ 13,742 $ 10,981 China 885 828 2,454 1,886 Other 3,950 3,265 12,313 8,801 Consolidated revenues $ 9,330 $ 8,521 $ 28,509 $ 21,668 (a) Revenues are attributed to countries based on customer location.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Oct. 02, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following: Nine Months Ended October 2, September 26, (In millions) 2021 2020 Statutory Federal Income Tax Rate 21 % 21 % Provision for Income Taxes at Statutory Rate $ 1,464 $ 910 Increases (Decreases) Resulting From: Foreign rate differential (159) (132) Income tax credits (205) (205) Global intangible low-taxed income 45 82 Foreign-derived intangible income (114) (53) Excess tax benefits from stock options and restricted stock units (96) (94) Intra-entity transfers (258) — Withholding taxes 106 10 State income taxes, net of federal tax 115 29 Other, net 8 (91) Provision for Income Taxes $ 906 $ 456
Summary of Income Tax Contingencies [Table Text Block]	A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows: (In millions) 2021 Balance at Beginning of Year $ 1,091 Additions for tax positions of current year 30 Additions for tax positions of prior years 15 Reductions for tax positions of prior years (2) Settlements (16) Balance at End of Period $ 1,118

Earnings per Share (Tables)

Earnings per Share (Tables)	9 Months Ended
	Oct. 02, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions except per share amounts) 2021 2020 2021 2020 Net Income $ 1,902 $ 1,933 $ 6,067 $ 3,877 Basic Weighted Average Shares 394 396 394 396 Plus Effect of: Stock options and restricted stock units 3 3 3 3 Diluted Weighted Average Shares 397 399 397 399 Basic Earnings per Share $ 4.83 $ 4.88 $ 15.41 $ 9.79 Diluted Earnings per Share $ 4.79 $ 4.84 $ 15.29 $ 9.71 Antidilutive Stock Options Excluded from Diluted Weighted Average Shares — — 1 1

Debt and Other Financing Arra_2

Debt and Other Financing Arrangements (Tables)	9 Months Ended
	Oct. 02, 2021
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Effective Interest Rate at October 2, October 2, December 31, (Dollars in millions) 2021 2021 2020 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated) $ — $ 611 3.00% 7-Year Senior Notes, Due 4/15/2023 — 1,000 4.15% 10-Year Senior Notes, Due 2/1/2024 — 1,000 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.94 % 1,159 1,222 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.42 % 928 977 4.133% 5-Year Senior Notes, Due 3/25/2025 4.32 % 1,100 1,100 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 742 782 3.65% 10-Year Senior Notes, Due 12/15/2025 3.77 % 350 350 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 812 855 2.95% 10-Year Senior Notes, Due 9/19/2026 3.19 % 1,200 1,200 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.66 % 580 611 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 696 733 3.20% 10-Year Senior Notes, Due 8/15/2027 3.39 % 750 750 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.78 % 928 977 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 696 733 1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 — 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 812 855 2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900 4.497% 10-Year Senior Notes, Due 3/25/2030 5.31 % 1,100 1,100 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.14 % 1,043 1,099 2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 — 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 696 733 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 812 855 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 1,043 1,099 2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 — 5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400 4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.99 % 1,159 1,222 Other 77 5 Total Borrowings at Par Value 21,833 21,919 Fair Value Hedge Accounting Adjustments — 25 Unamortized Discount (107) (102) Unamortized Debt Issuance Costs (128) (114) Total Borrowings at Carrying Value 21,598 21,728 Finance Lease Liabilities 109 7 Less: Short-term Obligations and Current Maturities 19 2,628 Long-term Obligations $ 21,688 $ 19,107
Schedule of Subsequent Events [Table Text Block]	Early in the fourth quarter, the company issued the following senior notes: (In millions) Principal Value Issued Floating Rate 18-Month Senior Notes, Due 4/18/2023 $ 1,000 Floating Rate 2-Year Senior Notes, Due 10/18/2023 $ 500 0.797% 2-Year Senior Notes, Due 10/18/2023 $ 1,350 Floating Rate 3-Year Senior Notes, Due 10/18/2024 $ 500 1.215% 3-Year Senior Notes, Due 10/18/2024 $ 2,500 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) € 1,750 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) € 1,500 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) € 1,250 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) € 750

Comprehensive Income (Tables)

Comprehensive Income (Tables)	9 Months Ended
	Oct. 02, 2021
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in each component of accumulated other comprehensive items, net of tax, are as follows: (In millions) Currency Unrealized Pension and Total Balance at December 31, 2020 $ (2,438) $ (91) $ (278) $ (2,807) Other comprehensive items before reclassifications 121 — 7 128 Amounts reclassified from accumulated other comprehensive items — 16 9 25 Net other comprehensive items 121 16 16 153 Balance at October 2, 2021 $ (2,317) $ (75) $ (262) $ (2,654)

Fair Value Measurements and F_2

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	9 Months Ended
	Oct. 02, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	October 2, 2021 and December 31, 2020: October 2, Quoted Significant Significant (In millions) 2021 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 10,518 $ 10,518 $ — $ — Investments in common stock, mutual funds and other similar instruments 61 61 — — Warrants 18 — 18 — Insurance contracts 178 — 178 — Derivative contracts 75 — 75 — Total Assets $ 10,850 $ 10,579 $ 271 $ — Liabilities Derivative contracts $ 4 $ — $ 4 $ — Contingent consideration 171 — — 171 Total Liabilities $ 175 $ — $ 4 $ 171 December 31, Quoted Significant Significant (In millions) 2020 (Level 1) (Level 2) (Level 3) Assets Cash equivalents $ 8,971 $ 8,971 $ — $ — Investments in common stock, mutual funds and other similar instruments 21 21 — — Warrants 7 — 7 — Insurance contracts 157 — 157 — Derivative contracts 28 — 28 — Total Assets $ 9,184 $ 8,992 $ 192 $ — Liabilities Derivative contracts $ 132 $ — $ 132 $ — Contingent consideration 70 — — 70 Total Liabilities $ 202 $ — $ 132 $ 70
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones), of the contingent consideration. Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Contingent Consideration Beginning Balance $ 149 $ 53 $ 70 $ 55 Acquisitions (including assumed balances) — — 179 — Payments (1) (1) (43) (3) Changes in fair value included in earnings 23 (8) (35) (8) Ending Balance $ 171 $ 44 $ 171 $ 44
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	The following table provides the aggregate notional value of outstanding derivative contracts. October 2, December 31, (In millions) 2021 2020 Notional Amount Interest rate swaps - fair value hedges $ — $ 1,000 Cross-currency interest rate swaps - designated as net investment hedges 900 900 Currency exchange contracts 4,823 5,206 While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value – Assets Fair Value – Liabilities October 2, December 31, October 2, December 31, (In millions) 2021 2020 2021 2020 Derivatives Designated as Hedging Instruments Interest rate swaps (a) $ — $ 25 $ — $ — Cross-currency interest rate swaps (a) 10 — 4 46 Derivatives Not Designated as Hedging Instruments Currency exchange contracts (b) 65 3 — 86 Total Derivatives $ 75 $ 28 $ 4 $ 132 (a) The fair values of the interest rate swaps and cross-currency interest rate swaps are included in the accompanying balance sheet under the caption other assets or other long-term liabilities. (b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses. The following amounts related to cumulative basis adjustments for fair value hedges were included in the accompanying balance sheet under the caption long-term obligations: Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability October 2, December 31, October 2, December 31, (In millions) 2021 2020 2021 2020 Long-term Obligations $ — $ 1,020 $ — $ 25
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	Gain (Loss) Recognized Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Fair Value Hedging Relationships Interest rate swaps Hedged long-term obligations - included in other income (expense) $ — $ — $ 25 $ (43) Derivatives designated as hedging instruments - included in other income (expense) — — (3) 43 Derivatives Designated as Cash Flow Hedges Interest rate swaps Included in unrealized losses on hedging instruments within other comprehensive items — — — (85) Amount reclassified from accumulated other comprehensive items to other expense (2) (8) (21) (14) Financial Instruments Designated as Net Investment Hedges Foreign currency-denominated debt Included in currency translation adjustment within other comprehensive items 297 (295) 673 (276) Cross-currency interest rate swaps Included in currency translation adjustment within other comprehensive items 20 (30) 52 (30) Included in other income (expense) 2 2 6 9 Gain (Loss) Recognized Three Months Ended Nine Months Ended October 2, September 26, October 2, September 26, (In millions) 2021 2020 2021 2020 Derivatives Not Designated as Hedging Instruments Currency exchange contracts Included in cost of product revenues 7 (2) 8 (2) Included in other income (expense) (8) 51 147 7 Cross-currency interest rate swaps Included in other income (expense) — 1 — (9)
Fair Value, by Balance Sheet Grouping [Table Text Block]	The carrying value and fair value of the company’s debt instruments are as follows: October 2, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) Value Value Value Value Senior notes $ 21,521 $ 23,418 $ 21,723 $ 24,653 Other 77 77 5 5 $ 21,598 $ 23,495 $ 21,728 $ 24,658 The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The carrying value and fair value of the company’s debt instruments are as follows: October 2, 2021 December 31, 2020 Carrying Fair Carrying Fair (In millions) Value Value Value Value Senior notes $ 21,521 $ 23,418 $ 21,723 $ 24,653 Other 77 77 5 5 $ 21,598 $ 23,495 $ 21,728 $ 24,658 The fair value of debt instruments was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends which represent level 2 measurements.

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Oct. 02, 2021
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Nine Months Ended October 2, September 26, (In millions) 2021 2020 Non-cash Investing and Financing Activities Acquired but unpaid property, plant and equipment $ 257 $ 134 Fair value of acquisition contingent consideration 179 — Declared but unpaid dividends 104 88 Issuance of stock upon vesting of restricted stock units 237 209
Restrictions on Cash and Cash Equivalents [Table Text Block]	Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows: October 2, December 31, (In millions) 2021 2020 Cash and Cash Equivalents $ 12,027 $ 10,325 Restricted Cash Included in Other Current Assets 20 10 Restricted Cash Included in Other Assets 1 1 Cash, Cash Equivalents and Restricted Cash $ 12,048 $ 10,336

Restructuring and Other Costs (

Restructuring and Other Costs (Tables)	9 Months Ended
	Oct. 02, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	During the third quarter of 2021, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ — $ 23 $ (3) $ 20 Analytical Instruments — 1 2 3 Specialty Diagnostics — — 14 14 Laboratory Products and Services — 26 (3) 23 Corporate — 9 8 17 $ — $ 59 $ 18 $ 77 During the first nine months of 2021, the company recorded net restructuring and other costs (income) by segment as follows: (In millions) Cost of Selling, Restructuring Total Life Sciences Solutions $ 8 $ (24) $ 125 $ 109 Analytical Instruments — 1 5 6 Specialty Diagnostics — (2) 17 15 Laboratory Products and Services — 49 (5) 44 Corporate — 9 9 18 $ 8 $ 33 $ 151 $ 192
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet. (In millions) Total (a) Balance at December 31, 2020 21 Net restructuring charges incurred in 2021 (b) 23 Payments (31) Currency translation (1) Balance at October 2, 2021 $ 12 (a) The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020	Jul. 03, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw Materials	$ 1,840		$ 1,840			$ 1,305
Work in Process	680		680			540
Finished Goods	2,386		2,386			2,184
Inventories	4,906		4,906			4,029
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	4,906		4,906			$ 4,029
Product [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of revenues	(3,298)	$ (3,001)	(9,977)	$ (7,732)
Change in Accounting Principle, Other
Inventory Disclosure [Abstract]
Inventories	33		33
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	33		33
Percentage of LIFO Inventory					5.00%
Change in Accounting Principle, Other | Laboratory Products and Services [Member]
Inventory Disclosure [Abstract]
Inventories	20		20
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	20		20
Change in Accounting Principle, Other | Specialty Diagnostics [Member]
Inventory Disclosure [Abstract]
Inventories	13		13
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Inventories	13		$ 13
Change in Accounting Principle, Other | Product [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of revenues	33
Change in Accounting Principle, Other | Product [Member] | Laboratory Products and Services [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of revenues	20
Change in Accounting Principle, Other | Product [Member] | Specialty Diagnostics [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cost of revenues	$ 13

Acquisitions Purchase Price (De

Acquisitions Purchase Price (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 30, 2021	Feb. 25, 2021	Jan. 15, 2021	Dec. 31, 2021	Oct. 02, 2021	Sep. 26, 2020	Apr. 15, 2021
Business Acquisition [Line Items]
Net Cash Consideration					$ 1,519	$ 3
Purchase Price
Fair value of contingent consideration					$ 179
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					9 years
Customer Relationships [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					14 years
Product Technology [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					7 years
Tradenames [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					3 years
PPD, Inc [Member]
Business Acquisition [Line Items]
Percent of PPD's outstanding shares that have approved the proposed acquisition							60.00%
European Viral Vector Manufacturing Business
Business Acquisition [Line Items]
Net Cash Consideration			$ 834
Purchase Price
Cash paid			853
Cash acquired			(19)
Total Purchase Price			834
Net Assets Acquired [Abstract]
Current assets			39
Property, plant and equipment			59
Goodwill			603
Other assets			4
Contract Liabilities			(59)
Deferred tax liabilities			(80)
Finance lease liabilities			(24)
Other liabilities assumed			(35)
Net Assets Acquired			834
European Viral Vector Manufacturing Business | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			302
European Viral Vector Manufacturing Business | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 25
Mesa Biotech
Business Acquisition [Line Items]
Net Cash Consideration		$ 409
Purchase Price
Cash paid		423
Fair value of contingent consideration		65
Cash acquired		(14)
Total Purchase Price		474
Net Assets Acquired [Abstract]
Current assets		54
Property, plant and equipment		2
Goodwill		239
Other assets		4
Deferred tax liabilities		(72)
Finance lease liabilities		(1)
Other liabilities assumed		(33)
Net Assets Acquired		474
Mesa Biotech | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		279
Mesa Biotech | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		$ 2
Lengnau biologics manufacturing facility
Business Acquisition [Line Items]
Lessee, Lease Liability Payments Due	$ 555
Purchase Price
Fair value of contingent consideration	1
Purchase price payable	17
Total Purchase Price	18
Net Assets Acquired [Abstract]
Property, plant and equipment	92
Goodwill	18
Other assets	361
Finance lease liabilities	(82)
Other liabilities assumed	(371)
Net Assets Acquired	$ 18
Other [Member]
Purchase Price
Cash paid					$ 287
Fair value of contingent consideration					113
Cash acquired					(11)
Total Purchase Price					389
Net Assets Acquired [Abstract]
Current assets					10
Property, plant and equipment					3
Goodwill					190
Contract Liabilities					(1)
Deferred tax liabilities					(28)
Other liabilities assumed					(10)
Net Assets Acquired					389
Other [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					2
Other [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					220
Other [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					$ 3
Forecast [Member] | PPD, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition, Share Price				$ 47.50
Purchase Price
Cash paid				$ 17,400
Net Assets Acquired [Abstract]
Debt assumed				$ (3,500)

Revenue (Details)

Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 9,330	$ 8,521	$ 28,509	$ 21,668
North America [Member]
Disaggregation of Revenue [Line Items]
Revenues	4,662	4,587	14,292	11,418
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,557	2,032	8,037	5,464
Asia Pacific [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,836	1,607	5,294	4,054
Other Regions [Member]
Disaggregation of Revenue [Line Items]
Revenues	275	295	886	732
Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	5,544	4,956	16,880	12,214
Instruments [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,816	1,826	5,550	4,448
Service [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 1,970	$ 1,739	$ 6,079	$ 5,006

Revenue Performance Obligations

Revenue Performance Obligations (Details) $ in Millions	Oct. 02, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 14,490
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-02
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Percentage	76.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Contract Assets and Liabilities

Contract Assets and Liabilities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020	Dec. 31, 2020
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Current Contract Assets, Net	$ 808		$ 808		$ 731
Noncurrent Contract Assets, Net	11		11		11
Current Contract Liabilities	1,442		1,442		1,271
Noncurrent Contract Liabilities	822		822		$ 763
Revenue recognized that was included in the current contract liability balance at the beginning of the period	$ 173	$ 142	$ 1,100	$ 773

Business Segment Information (D

Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Segment Reporting Information [Line Items]
Revenues	$ 9,330	$ 8,521	$ 28,509	$ 21,668
Operating Income	2,278	2,426	7,490	4,723
Cost of revenues charges			(8)
Selling, general and administrative (charges) credits	(59)		(33)
Restructuring and other costs	(18)	(17)	(151)	(67)
Amortization of acquisition-related intangible assets			(1,295)	(1,256)
Interest Income	9	9	32	53
Interest Expense	(128)	(144)	(375)	(407)
Other Income (Expense)	14	(39)	(174)	(36)
Income before income taxes	2,173	2,252	6,973	4,333
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges			(8)
Selling, general and administrative (charges) credits	(23)		24
Restructuring and other costs	3		(125)
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative (charges) credits	(1)		(1)
Restructuring and other costs	(2)		(5)
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative (charges) credits			2
Restructuring and other costs	(14)		(17)
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative (charges) credits	(26)		(49)
Restructuring and other costs	3		5
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	2,778	2,803	8,977	6,044
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	3,721	3,424	11,481	7,800
Operating Income	1,821	1,879	5,818	3,788
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues	1,476	1,336	4,344	3,488
Operating Income	264	171	816	477
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues	1,362	1,430	4,212	3,376
Operating Income	310	398	983	848
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues	3,487	3,112	10,667	8,629
Operating Income	383	355	1,360	931
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues	(716)	(781)	(2,195)	(1,625)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	0	(1)	(8)	(5)
Selling, general and administrative (charges) credits	(59)	55	(33)	7
Restructuring and other costs	(18)	(17)	(151)	(67)
Amortization of acquisition-related intangible assets	$ (423)	$ (414)	$ (1,295)	$ (1,256)

Geographical Information (Detai

Geographical Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 9,330	$ 8,521	$ 28,509	$ 21,668
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	4,495	4,428	13,742	10,981
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	885	828	2,454	1,886
All Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 3,950	$ 3,265	$ 12,313	$ 8,801
[1]	Revenues are attributed to countries based on customer location.

Income Taxes Rate Reconciliatio

Income Taxes Rate Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory Federal Income Tax Rate			21.00%	21.00%
Provision for Income Taxes at Statutory Rate			$ 1,464	$ 910
Foreign rate differential			(159)	(132)
Income tax credits			(205)	(205)
Global intangible low-taxed income			45	82
Foreign-derived intangible income			(114)	(53)
Excess tax benefits from stock options and restricted stock units			(96)	(94)
Intra-entity transfers			(258)
Withholding taxes			106	10
State income taxes, net of federal tax			115	29
Other, net			8	(91)
Provision for Income Taxes	$ 271	$ 319	$ 906	$ 456

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	9 Months Ended
	Oct. 02, 2021USD ($)
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at Beginning of Year	$ 1,091
Additions for tax positions of current year	30
Additions for tax positions of prior years	15
Reductions for tax positions of prior years	(2)
Settlements	(16)
Balance at End of Period	$ 1,118

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Earnings Per Share [Abstract]
Net income	$ 1,902	$ 1,933	$ 6,067	$ 3,877
Basic Weighted Average Shares	394	396	394	396
Effect of Stock Options and Restricted Units	3	3	3	3
Diluted Weighted Average Shares	397	399	397	399
Basic Earnings Per Share (in dollars per share)	$ 4.83	$ 4.88	$ 15.41	$ 9.79
Diluted Earnings Per Share (in dollars per share)	$ 4.79	$ 4.84	$ 15.29	$ 9.71
Antidilutive Stock Options Excluded from Diluted Weighted Average Shares	0	0	1	1

Debt Outstanding Debt (Details)

Debt Outstanding Debt (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Apr. 03, 2021	Oct. 02, 2021	Sep. 26, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Total Borrowings at Par Value		$ 21,833		$ 21,919
Fair Value Hedge Accounting Adjustments				25
Unamortized Discount		(107)		(102)
Unamortized Debt Issuance Costs		(128)		(114)
Total Borrowings at Carrying Value		21,598		21,728
Finance Lease Liabilities		109		7
Less: Short-term Obligations and Current Maturities		19		2,628
Long-term Obligations		21,688		19,107
Losses on Extinguishment of Debt	$ 197	197	$ 0
Proceeds from Hedge, Financing Activities	$ 22
Senior Notes [Member]
Debt Instrument [Line Items]
Total Borrowings at Carrying Value		$ 21,521		21,723
Debt Instrument, Call Feature		Each of the notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest.
Senior Notes [Member] | 2.15% 7-Year Senior Notes, Due 7/21/2022 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2.15%
Debt Instrument, Term		7 years
Debt Instrument, Maturity Date		Jul. 21, 2022
Total Borrowings at Par Value				611
Senior Notes [Member] | 3.00% 7-Year Senior Notes, Due 4/15/2023
Debt Instrument [Line Items]
Stated Interest Rate		3.00%
Debt Instrument, Term		7 years
Debt Instrument, Maturity Date		Apr. 15, 2023
Total Borrowings at Par Value				1,000
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024
Debt Instrument [Line Items]
Stated Interest Rate		4.15%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Feb. 1, 2024
Total Borrowings at Par Value				1,000
Senior Notes [Member] | 0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.75%
Debt Instrument, Term		8 years
Debt Instrument, Maturity Date		Sep. 12, 2024
Effective Interest Rate		0.94%
Total Borrowings at Par Value		$ 1,159		1,222
Senior Notes [Member] | 0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.125%
Debt Instrument, Term		5 years 6 months
Debt Instrument, Maturity Date		Mar. 1, 2025
Effective Interest Rate		0.42%
Total Borrowings at Par Value		$ 928		977
Senior Notes [Member] | 4.133% 5-Year Senior Notes, Due 3/25/2025
Debt Instrument [Line Items]
Stated Interest Rate		4.133%
Debt Instrument, Term		5 years
Debt Instrument, Maturity Date		Mar. 25, 2025
Effective Interest Rate		4.32%
Total Borrowings at Par Value		$ 1,100		1,100
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2.00%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Apr. 15, 2025
Effective Interest Rate		2.10%
Total Borrowings at Par Value		$ 742		782
Senior Notes [Member] | 3.65% 10-Year Senior Notes, Due 12/15/2025
Debt Instrument [Line Items]
Stated Interest Rate		3.65%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Dec. 15, 2025
Effective Interest Rate		3.77%
Total Borrowings at Par Value		$ 350		350
Senior Notes [Member] | 1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.40%
Debt Instrument, Term		8 years 6 months
Debt Instrument, Maturity Date		Jan. 23, 2026
Effective Interest Rate		1.53%
Total Borrowings at Par Value		$ 812		855
Senior Notes [Member] | 2.95% 10-Year Senior Notes, Due 9/19/2026
Debt Instrument [Line Items]
Stated Interest Rate		2.95%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Sep. 19, 2026
Effective Interest Rate		3.19%
Total Borrowings at Par Value		$ 1,200		1,200
Senior Notes [Member] | 1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.45%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Mar. 16, 2027
Effective Interest Rate		1.66%
Total Borrowings at Par Value		$ 580		611
Senior Notes [Member] | 1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.75%
Debt Instrument, Term		7 years
Debt Instrument, Maturity Date		Apr. 15, 2027
Effective Interest Rate		1.97%
Total Borrowings at Par Value		$ 696		733
Senior Notes [Member] | 3.20% 10-Year Senior Notes, Due 8/15/2027
Debt Instrument [Line Items]
Stated Interest Rate		3.20%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Aug. 15, 2027
Effective Interest Rate		3.39%
Total Borrowings at Par Value		$ 750		750
Senior Notes [Member] | 0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.50%
Debt Instrument, Term		8 years 6 months
Debt Instrument, Maturity Date		Mar. 1, 2028
Effective Interest Rate		0.78%
Total Borrowings at Par Value		$ 928		977
Senior Notes [Member] | 1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.375%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Sep. 12, 2028
Effective Interest Rate		1.46%
Total Borrowings at Par Value		$ 696		733
Senior Notes [Member] | 1.750% 7-Year Senior Notes, Due 10/15/2028
Debt Instrument [Line Items]
Stated Interest Rate		1.75%
Debt Instrument, Term		7 years
Debt Instrument, Maturity Date		Oct. 15, 2028
Effective Interest Rate		1.89%
Total Borrowings at Par Value		$ 700
Senior Notes [Member] | 1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.95%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Jul. 24, 2029
Effective Interest Rate		2.08%
Total Borrowings at Par Value		$ 812		855
Senior Notes [Member] | 2.60% 10-Year Senior Notes, Due 10/1/2029
Debt Instrument [Line Items]
Stated Interest Rate		2.60%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Oct. 1, 2029
Effective Interest Rate		2.74%
Total Borrowings at Par Value		$ 900		900
Senior Notes [Member] | 4.497% 10-Year Senior Notes, Due 3/25/2030
Debt Instrument [Line Items]
Stated Interest Rate		4.497%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Mar. 25, 2030
Effective Interest Rate		5.31%
Total Borrowings at Par Value		$ 1,100		1,100
Senior Notes [Member] | 0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		0.875%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Oct. 1, 2031
Effective Interest Rate		1.14%
Total Borrowings at Par Value		$ 1,043		1,099
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 10/15/2031
Debt Instrument [Line Items]
Stated Interest Rate		2.00%
Debt Instrument, Term		10 years
Debt Instrument, Maturity Date		Oct. 15, 2031
Effective Interest Rate		2.23%
Total Borrowings at Par Value		$ 1,200
Senior Notes [Member] | 2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2.375%
Debt Instrument, Term		12 years
Debt Instrument, Maturity Date		Apr. 15, 2032
Effective Interest Rate		2.55%
Total Borrowings at Par Value		$ 696		733
Senior Notes [Member] | 2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		2.875%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Jul. 24, 2037
Effective Interest Rate		2.94%
Total Borrowings at Par Value		$ 812		855
Senior Notes [Member] | 1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.50%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Oct. 1, 2039
Effective Interest Rate		1.73%
Total Borrowings at Par Value		$ 1,043		1,099
Senior Notes [Member] | 2.80% 20-Year Senior Notes, Due 10/15/2041
Debt Instrument [Line Items]
Stated Interest Rate		2.80%
Debt Instrument, Term		20 years
Debt Instrument, Maturity Date		Oct. 15, 2041
Effective Interest Rate		2.90%
Total Borrowings at Par Value		$ 1,200
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044
Debt Instrument [Line Items]
Stated Interest Rate		5.30%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Feb. 1, 2044
Effective Interest Rate		5.37%
Total Borrowings at Par Value		$ 400		400
Senior Notes [Member] | 4.10% 30-Year Senior Notes, Due 8/15/2047
Debt Instrument [Line Items]
Stated Interest Rate		4.10%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Aug. 15, 2047
Effective Interest Rate		4.23%
Total Borrowings at Par Value		$ 750		750
Senior Notes [Member] | 1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)
Debt Instrument [Line Items]
Stated Interest Rate		1.875%
Debt Instrument, Term		30 years
Debt Instrument, Maturity Date		Oct. 1, 2049
Effective Interest Rate		1.99%
Total Borrowings at Par Value		$ 1,159		1,222
Other Debt [Member]
Debt Instrument [Line Items]
Total Borrowings at Par Value		77		5
Total Borrowings at Carrying Value		$ 77		$ 5

Debt Short-term Financing (Deta

Debt Short-term Financing (Details)	9 Months Ended
	Oct. 02, 2021USD ($)
Revolving Credit Facility [Member]
Short-term Financing [Line Items]
Maximum Borrowing Capacity	$ 3,000,000,000
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3.5
Line of Credit Facility, Amount Outstanding	$ 0
Letters of Credit Outstanding, Amount	4,000,000
Commercial Paper Programs [Member]
Short-term Financing [Line Items]
Short-term Debt	$ 0
Commercial Paper Programs [Member] | U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Commercial Paper Programs [Member] | Euro Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	183 days
Bridge Loan [Member]
Short-term Financing [Line Items]
Payments of Financing Costs	$ 35,000,000

Subsequent Events (Details)

Subsequent Events (Details) € in Millions, $ in Millions	1 Months Ended
	Oct. 31, 2021USD ($)	Oct. 31, 2021EUR (€)	Oct. 02, 2021USD ($)	Dec. 31, 2020USD ($)
Subsequent Event [Line Items]
Total Borrowings at Par Value			$ 21,833	$ 21,919
Subsequent Event [Member] | Senior Notes [Member] | Floating Rate 18-Month Senior Notes, Due 4/18/2023
Subsequent Event [Line Items]
Debt Instrument, Term	18 months
Debt Instrument, Maturity Date	Apr. 18, 2023
Total Borrowings at Par Value	$ 1,000
Subsequent Event [Member] | Senior Notes [Member] | Floating Rate 2-Year Senior Notes, Due 10/18/2023
Subsequent Event [Line Items]
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Oct. 18, 2023
Total Borrowings at Par Value	$ 500
Subsequent Event [Member] | Senior Notes [Member] | 0.797% 2-Year Senior Notes, Due 10/18/2023
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.797%	0.797%
Debt Instrument, Term	2 years
Debt Instrument, Maturity Date	Oct. 18, 2023
Total Borrowings at Par Value	$ 1,350
Subsequent Event [Member] | Senior Notes [Member] | Floating Rate 3-Year Senior Notes, Due 10/18/2024
Subsequent Event [Line Items]
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	Oct. 18, 2024
Total Borrowings at Par Value	$ 500
Subsequent Event [Member] | Senior Notes [Member] | 1.215% 3-Year Senior Notes, Due 10/18/2024
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.215%	1.215%
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	Oct. 18, 2024
Total Borrowings at Par Value	$ 2,500
Subsequent Event [Member] | Senior Notes [Member] | 0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	0.80%	0.80%
Debt Instrument, Term	9 years
Debt Instrument, Maturity Date	Oct. 18, 2030
Total Borrowings at Par Value | €		€ 1,750
Subsequent Event [Member] | Senior Notes [Member] | 1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.125%	1.125%
Debt Instrument, Term	12 years
Debt Instrument, Maturity Date	Oct. 18, 2033
Total Borrowings at Par Value | €		€ 1,500
Subsequent Event [Member] | Senior Notes [Member] | 1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.625%	1.625%
Debt Instrument, Term	20 years
Debt Instrument, Maturity Date	Oct. 18, 2041
Total Borrowings at Par Value | €		€ 1,250
Subsequent Event [Member] | Senior Notes [Member] | 2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.00%	2.00%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	Oct. 18, 2051
Total Borrowings at Par Value | €		€ 750

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	3 Months Ended
	Sep. 26, 2020USD ($)
Cost of Product Revenues [Member] | Analytical Instruments [Member] | Inventories [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Inventory, Firm Purchase Commitment, Loss	$ 108

Comprehensive Income (Details)

Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 36,854	$ 29,875	$ 34,507	$ 29,675
Other comprehensive items before reclassifications			128
Amounts reclassified from accumulated other comprehensive items			25
Total other comprehensive items	(24)	19	153	(291)
Balance	38,710	31,824	38,710	31,824
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(2,438)
Other comprehensive items before reclassifications			121
Total other comprehensive items			121
Balance	(2,317)		(2,317)
Unrealized Losses on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(91)
Amounts reclassified from accumulated other comprehensive items			16
Total other comprehensive items			16
Balance	(75)		(75)
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance			(278)
Other comprehensive items before reclassifications			7
Amounts reclassified from accumulated other comprehensive items			9
Total other comprehensive items			16
Balance	(262)		(262)
Accumulated Other Comprehensive Items [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(2,630)	(2,989)	(2,807)	(2,679)
Total other comprehensive items	(24)	19	153	(291)
Balance	$ (2,654)	$ (2,970)	$ (2,654)	$ (2,970)

Fair Value Measurements, Assets

Fair Value Measurements, Assets and Liabilities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Assets [Abstract]
Cash equivalents	$ 10,518	$ 8,971
Investments in common stock, mutual funds and other similar instruments	61	21
Warrants	18	7
Insurance contracts	178	157
Derivative contracts	75	28
Total Assets	10,850	9,184
Liabilities [Abstract]
Derivative contracts	4	132
Contingent consideration	171	70
Total Liabilities	175	202
Quoted Prices in Active Markets (Level I) [Member]
Assets [Abstract]
Cash equivalents	10,518	8,971
Investments in common stock, mutual funds and other similar instruments	61	21
Total Assets	10,579	8,992
Significant Other Observable Inputs (Level 2) [Member]
Assets [Abstract]
Warrants	18	7
Insurance contracts	178	157
Derivative contracts	75	28
Total Assets	271	192
Liabilities [Abstract]
Derivative contracts	4	132
Total Liabilities	4	132
Significant Unobservable Inputs (Level 3) [Member]
Liabilities [Abstract]
Contingent consideration	171	70
Total Liabilities	$ 171	$ 70

Fair Value Measurements and F_3

Fair Value Measurements and Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 149	$ 53	$ 70	$ 55
Acquisitions (including assumed balances)			179
Payments	(1)	(1)	(43)	(3)
Changes in fair value included in earnings	23	(8)	(35)	(8)
Ending Balance	$ 171	$ 44	$ 171	$ 44
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]			Selling, general and administrative expenses

Fair Value Measurements, Deriva

Fair Value Measurements, Derivative Assets & Liabilities (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability		$ 25
Long-term Obligations [Member]
Derivatives, Fair Value [Line Items]
Hedged Liability, Fair Value Hedge		1,020
Cumulative Amount of Fair Value Hedging Adjustment - Increase (Decrease) Included in Carrying Amount of Liability		25
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets		25
Interest Rate Swaps [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives		1,000
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 10
Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member] | Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities	4	46
Cross Currency Interest Rate Contract [Member] | Net Investment Hedging [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	900	900
Currency Exchange Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional Amount Of Derivatives	4,823	5,206
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	65	3
Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instrument [Member] | Other Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Derivative Liabilities		86
Fair Value, Recurring [Member]
Derivatives, Fair Value [Line Items]
Derivative Assets	75	28
Derivative Liabilities	$ 4	$ 132

Fair Value Measurements, Deri_2

Fair Value Measurements, Derivative Instruments, Gains & Losses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020
Cross Currency Interest Rate Contract [Member] | Other Income (Expense) [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net		$ 1		$ (9)
Currency Exchange Contracts [Member] | Cost of Product Revenues [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 7	(2)	$ 8	(2)
Currency Exchange Contracts [Member] | Other Income (Expense) [Member] | Derivatives Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	(8)	51	147	7
Fair Value Hedging [Member] | Interest Rate Swaps [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Hedged long-term obligations in Fair Value Hedge			25	(43)
Gain (Loss) on Derivative, Net			(3)	43
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in OCI on Cash Flow Hedge				(85)
Cash Flow Hedging [Member] | Interest Rate Swaps [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Cash Flow Hedge Reclassified from AOCI	(2)	(8)	(21)	(14)
Net Investment Hedging [Member] | Foreign currency-denominated debt [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	297	(295)	673	(276)
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	20	(30)	52	(30)
Net Investment Hedging [Member] | Cross Currency Interest Rate Contract [Member] | Other Income (Expense) [Member] | Derivatives Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative, Net	$ 2	$ 2	$ 6	$ 9

Fair Value of Other Instruments

Fair Value of Other Instruments (Details) - USD ($) $ in Millions	Oct. 02, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	$ 23,495	$ 24,658
Long-term Debt	21,598	21,728
Senior Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	23,418	24,653
Long-term Debt	21,521	21,723
Other Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	77	5
Long-term Debt	$ 77	$ 5

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 02, 2021	Sep. 26, 2020	Dec. 31, 2020	Dec. 31, 2019
Non-cash Investing and Financing Activities [Abstract]
Acquired but unpaid property, plant and equipment	$ 257	$ 134
Fair value of contingent consideration	179
Declared but unpaid dividends	104	88
Issuance of stock upon vesting of restricted stock units	237	209
Cash and Cash Equivalents	12,027		$ 10,325
Restricted Cash Included in Other Current Assets	20		10
Restricted Cash Included in Other Assets	1		1
Cash, Cash Equivalents and Restricted Cash	$ 12,048	$ 7,570	$ 10,336	$ 2,422
Restricted Cash and Cash Equivalents, Current, Asset, Statement of Financial Position [Extensible List]	Other current assets
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	Other Assets

Restructuring and Other Costs_2

Restructuring and Other Costs (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2021	Sep. 26, 2020	Oct. 02, 2021	Sep. 26, 2020	Nov. 04, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Percentage of Total Workforce Eliminated less than				1.00%
Cost of Revenues				$ 8
Selling, General and Administrative Expenses		$ 59		33
Restructuring and other costs		18	$ 17	151	$ 67
Total Restructuring and Other Costs (Income)		77		192
Restructuring and Related Costs, Cash Costs	[1],[2]			23
Restructuring and Related Costs, Other Costs (Income)				128
Life Sciences Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Cost of Revenues				8
Selling, General and Administrative Expenses		23		(24)
Restructuring and other costs		(3)		125
Total Restructuring and Other Costs (Income)		20		109
Impairment of Intangible Assets (Excluding Goodwill)				110
Analytical Instruments [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		1		1
Restructuring and other costs		2		5
Total Restructuring and Other Costs (Income)		3		6
Specialty Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses				(2)
Restructuring and other costs		14		17
Total Restructuring and Other Costs (Income)		14		15
Laboratory Products and Services [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		26		49
Restructuring and other costs		(3)		(5)
Total Restructuring and Other Costs (Income)		23		44
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Selling, General and Administrative Expenses		9		9
Restructuring and other costs		8		9
Total Restructuring and Other Costs (Income)		$ 17		$ 18
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Identified Future Restructuring Costs						$ 25
[1]	Excludes $128 million of net charges, principally for impairment of acquired technology, compensation contractually due and paid to employees of acquired businesses at the date of acquisition, fixed asset write-downs, and charges associated with pre-acquisition related matters.
[2]	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.

Restructuring Reserves (Details

Restructuring Reserves (Details) $ in Millions	9 Months Ended
	Oct. 02, 2021USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 21	[1]
Net restructuring charges incurred in 2021 (b)	23	[1],[2]
Payments	(31)	[1]
Currency translation	(1)
Ending balance	12	[1]
Restructuring and Related Costs, Other Costs (Income)	$ 128
Restructuring Reserve, Expected Final Year of Payments	2021
[1]	The movements in the restructuring liability principally consist of severance and other costs such as relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
[2]	Excludes $128 million of net charges, principally for impairment of acquired technology, compensation contractually due and paid to employees of acquired businesses at the date of acquisition, fixed asset write-downs, and charges associated with pre-acquisition related matters.